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Ovarian carcinoma is the most lethal gynecologic malignancy.
1,2 There are several
morphological subtypes of ovarian carcinoma and serous type is the most common. The
molecular tumorigenesis leading to this heterogeneous group of ovarian cancers is mostly
unknown because of the lack of a universal tumor progression model. However, based on
several clinicopathologic and molecular genetic studies, a dualistic model of ovarian
serous carcinogenesis was recently proposed and is now gaining widespread acceptance.
2-4
It is presumed that low-grade serous carcinoma develops in a stepwise manner such as an
adenoma-carcinoma sequence in which a benign serous cystadenoma develops into a usual
serous borderline tumor, a noninvasive micropapillary serous carcinoma, and finally to a
low-grade serous carcinoma.
2 By contrast, the more common high-grade serous carcinoma
develops in a de novo manner directly from ovarian surface epithelium or the epithelium of
cortical inclusion cysts.
3
KRAS and its effector BRAF are members of the Ras/Raf/MEK/extracellular signal-
regulated kinase/mitogen-activated protein kinase pathway, which is a well-characterized
signaling mechanism that mediates cellular responses to growth signals.
5 In this pathway,
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mutation was first reported in malignant melanoma, lung, and
papillary thyroid carcinoma.
6-9 In non-invasive and invasive
ovarian carcinoma, mutation of KRAS and BRAF has
previously been described with KRAS mutation which was
mostly detected in mucinous ovarian tumor and in serous
borderline tumors, but not in invasive serous carcinoma.
2-4,10-15
TP53 is a tumorsuppressor gene that is located on the short arm
of chromosome 17 and encodes a 53-kDa nuclear protein that is
involved in the regulation of cell growth. Mutation of the TP53
gene is the most common mutation in human cancers.
16  It has
been suggested that p53 protein alterations due to missense
mutations and loss of the p53 protein by nonsense or frame-
shift mutations might play important roles in clonal expansion
of neoplastic cells.
17 Recently, the dualistic pathway was
supported by molecular genetic differences in the frequency of
KRAS, BRAF, and TP53 mutations between low-grade and
high-grade serous carcinomas, with KRAS and BRAF mutations
being more frequent and TP53 mutations being less common in
low-grade serous carcinomas.
2,4,14,18
Despite increasing acceptance of the dualistic model, relatively
few studies have attempted to provide evidence that supports or
refutes this carcinogenesis model. Determination of the
molecular pathways involved in the development of ovarian
serous carcinoma would markedly improve our understanding
of its pathogenesis, thereby providing a basis for the develop-
ment of new diagnostic tests and therapeutic strategies.
Therefore, the aim of this study was to analyze the molecular
genetic changes, including KRAS, BRAF, and TP53 mutations,
in Korean patients with ovarian serous carcinoma and to evaluate
the clinical outcomes in these 2 morphologically distinct
ovarian serous carcinomas.
Patient population and clinical data
The surgical pathology files of the Department of Obstetrics
and Gynecology, University of Ulsan, the Asan Medical
Center, during the period between January 1996 and August
2003 were searched for all cases of ovarian tumors diagnosed
as serous carcinomas. Of 164 cases identified, 104 cases with
available slides were enrolled for evaluation. The medical
records, including clinical outcomes, were reviewed. All
patients underwent surgery, and operative reports were
reviewed. The following information was taken from the
medical records: age, serum CA-125 level at the time of
diagnosis, International Federation of Gynecology and
Obstetrics (FIGO) stage, dimension of residual tumor, clinical
status at completion of primary chemotherapy, date of last
contact or death, and date of disease progression. The debulk-
ing operation was defined as optimal if the largest tumor mass
remaining was less than 2 cm in diameter.  
Histological evaluation
All slides were reviewed by a gynecologic pathologist. Cases
were classified according to the universal grading system.
19,20
Architectural grade, nuclear grade, and mitotic count were
scored each. Final grading was made as follows; total scores of
3-5 for Grade 1, total scores of 6-7 for Grade 2, and total scores
of 8-9 for Grade 3. In this study, Grade 2 carcinomas were
excluded in order to minimize difference of reproducibility. A
total of 100 patients with low-grade (Grade 1) or high-grade
(Grade 3) carcinoma were compared and analyzed.
Tissue section and tumor DNA samples 
Paraffin-embedded tissues from 20 low-grade serous
carcinomas and 17 high-grade serous carcinomas were used for
molecular genetic analysis. Of low-grade serous carcinoma
specimens, three were stage I, one was stage II, 13 were stage
III, and three were stage IV. In high-grade serous carcinoma
group, one with stage I, 1 with stage II, 14 with stage III and 1
with stage IV were included. The histological region of interest
was identified on a hematoxylin-eosin-stained section, which
was marked and cut into 3-6 serial sections. DNA was purified
from each section and the KRAS, BRAF, and TP53 genes were
assessed for mutations using digital PCR-based techniques. 
Amplification of KRAS, BRAF and T53 genes
Fifty nanograms of DNA were amplified in a 20 µL reaction
solution containing 2 µL of 10X buffer (Roche, Mannheim,
Germany), 1.7-2.5 mmol/L MgCl2, 0.3 µM each of primer pair
(primer sequences) (Table 1), 250 µM deoxynucleotide
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MATERIALS AND METHODS
Table 1. Primers Used for Amplification and Sequencing of 
KRAS, BRAF, and TP53Genes
Amplified fragment  Primer sequence
KRAS
Exon 2
F: 5’-TGACATGTTCTAATATAGTCAC
R: 5’-ACAAGATTTACCTCTATTGTTG
BRAF
Exon 15 
F: 5’-AGCAGCATCTCAGGGCCA
R: 5’-ATGCTTGCTCTGATAGGAAAATGA
TP53
Exon 5
F: 5’-TGCCGTCTTCCAGTTGCTTTATC
R: 5’-GCCAGACCTAAGAGCAATCAGTGAG
Exon 6
F: 5’-GGGGCTGGAGAGACGACA
R: 5’-TGGGGTTATAGGGAGGTCAAA
Exon 7
F: 5’-GGGCGACAGAGCGAGATTC
R: 5’-GGGGTCAGAGGCAAGCAGAG
Exon 8
F: 5’-GGAGTAGATGGAGCCTGGTTTTTTA
R: 5’-GGCAAGGAAAGGTGATAAAAGTG
Exon 9 
F: 5’-AAGCAAGCAGGACAAGAAGC
R: 5’-AAGAAAACGGCATTTTGAGTG
F, forward primer; R, reverse primer. triphosphate, and 2.5 units of DNA polymerase (Roche). The
Polymerase Chain Reaction (PCR) program for KRAS
amplification involved a single denaturation step at 95˚C for 5
minutes, followed by 35 cycles of 30 seconds at 95˚C
(denaturation), 30 seconds at 55˚C (annealing), and 40 seconds
at 72˚C (extension), followed by 10 minutes at 72˚C Amplifi-
cations of the BRAF and TP53 genes involved a 5-minute initial
denaturation step at 94˚C, followed by 30 cycles of 1 minute at
94˚C, 1 minute at 59˚C, and 1 minute at 72˚C, and a 10-minute
final extension step at 72˚C. PCR products were then 2% gel-
purified with a QIAgen gel extraction kit (Qiagen).
Direct sequencing 
DNA templates were processed for the DNA sequencing
reaction using the ABI-PRISM BigDye Terminator version 3.1
(Applied Biosystems, Foster, CA, USA) with both forward and
reverse sequence-specific primers. Twenty nanograms of
purified PCR products were added to 20 µL of sequencing
reaction solution containing 8 µL of BigDye Terminator v3.1
and 0.1 µM of the same PCR primer. Sequencing reactions
involved 25 cycles of 10 seconds at 96˚C, 5 seconds at 50˚C,
and 4 minutes at 60˚C Sequence data were generated with the
ABI PRISM 3100 DNA Analyzer (Applied Biosystems).
Sequences were analyzed by Sequencer 3.1.1 software
(Applied Biosystems) to compare genetic variations.
Statistical analysis 
SPSS 10.0 statistical software (Superior Performance Software
System, SPSS for Windows, Microsoft, Chicago, IL, USA)
was used for all statistical calculations. Categorical variables
were compared using the Chi-square and Fisher’s exact tests.
Mean, median, and standard deviation were calculated for
continuous variables. Progression-free survival and overall
survival times were estimated using the method of Kaplan and
Meier. The log-rank test was used to compare differences
between survival curves. p values of < 0.05 were considered
statistically significant. 
Clinical findings
In this study, 27 low-grade and 73 high-grade serous
carcinomas were selected. The mean age at diagnosis was
lower in patients with low-grade carcinoma than in those with
high-grade carcinoma (48.7 ± 15.0 years vs. 55.2 ± 10.7 years,
p = 0.045), and there were more premenopausal women in the
low-grade carcinoma group (p = 0.041). Serum CA-125
concentration, positive peritoneal cytology, lymph node
metastasis, optimality of debulking surgery, and adjuvant
chemotherapy were similar in 2 groups (Table 2). There was no
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RESULTS
Table 3. KRAS, BRAF, and TP53Mutations of Low-Grade and High-Grade Ovarian Serous Carcinoma 
Tumor No. of cases KRAS BRAF TP53
High-grade serous carcinoma  17 0 0 12 (70.6%)
Low-grade serous carcinoma  20 6 (30%) 2 (10%) 4 (20.0%)
Table 2. Characteristics of Patients with Ovarian Serous Carcinomas 
Low-grade High-grade
serous carcinoma serous carcinoma pvalue
(n = 27) (n = 73)
Median age (yrs) 44 (26 - 77) 54 (35 - 75) 0.043
Premenopause  16 (59.3%) 26 (35.6%) 0.041
Median CA-125 (U/mL)  (range) 379 (9.4 - 27,900) 1,225 (28.8 - 22,400) 0.501
FIGO Stage 0.191
I 6 (22.2%) 6 (8.2%)
II 1 (3.7%) 2 (2.7%)
III 17 (63.0%) 58 (79.5%)
IV 3 (11.1%) 7 (9.6%)
Cytology 
Adenocarcinoma 15 (55.6%) 54 (74.0%) 0.098
Lymph-node metastasis  10 (52.6%) 38 (71.7%) 0.161
Residual disease 0.633
< 2 cm  20 (74.1%) 50 (68.5%)
≥2 cm  7 (25.9%) 23 (31.5%)
Adjuvant chemotherapy  25 (92.6%) 66 (90.4%) 1.000significant difference in Federation of Gynaecology and
Obstetrics (FIGO) stage, however, early stage including stage I
or II accounted for larger portion in low grade group (25.9% vs.
11.0%, p = 0.110). During the median follow-up of 67 months
for the low-grade group and 45 months for the high-grade
group, there were 11 (40.7%) tumor-related deaths in patients
with low-grade carcinoma and 40 (54.8%) deaths in patients
with high-grade carcinoma (p = 0.262). There were no
statistically significant differences in progression-free and
overall survival rates according to FIGO stage between the two
groups, but the low-grade carcinoma group in early stage
(FIGO stage I and II) showed a trend for improved 5-year
progression-free survival, compared with the high-grade
carcinoma group (100% vs. 68.6%, p = 0.064) (Fig. 1).   
KRAS
We found that 6 (30%) low-grade serous carcinomas contained
activating KRAS mutations at codon 12 (mutations of GGT to
GAT), but these mutations were not found in high-grade serous
carcinomas (Table 3, Fig. 2). 
BRAF
BRAF mutations were not found in any of the high-grade
serous carcinomas, whereas the BRAF mutation was identified
only in low-grade serous carcinomas. Two cases (10%) of low-
grade carcinoma contained a mutation in exon 15, and codon
600 was affected (V600E) (Fig. 2). KRAS and BRAF muta-
tions were mutually exclusive.
TP53
TP53 mutations were found in 4 of the 20 (20.0%) cases of
low-grade serous carcinoma. Of these four mutations, three
were missense mutations and 1 was a mutation that affected the
splicing site. By contrast, mutations were found in 12 of the 17
(70.6%) cases of high-grade serous carcinoma, 6 of which were
missense mutations, 2 were nonsense mutations, and 4 were
deletion mutations (Fig. 3). The frequency of TP53 mutations
was significantly higher in high-grade than in low-grade serous
carcinomas (p = 0.009). 
The importance of stage and residual disease status as
prognostic factors in ovarian serous carcinoma is universally
accepted,
21 but the significance of histologic grade has been
questioned due to the lack of a uniform grading system and
poor reproducibility. Universal grading system has been used
with good reproducibility, and its prognostic use in cases of
ovarian epithelial tumors has been statistically supported.
19, 22 In
the present study, the patients with grade 1 and grade 3 except
grade 2 were selected to evaluate the clinical outcomes and
prognostic role of these 2, morphologically distinct, ovarian
KRAS, BRAF, and TP53 Mutation in Ovarian Serous Carcinomas
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Fig. 1. (A) progression-free survival in early stage, (B) progression-free survival
in advanced stage, and (C) overall survival of the patients with advanced stage. 
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DISCUSSIONserous carcinomas. We found that histologic grade did not have
a prognostic role in each FIGO stage, nevertheless, our findings
suggested clinical differences between low-grade serous
carcinoma and high-grade serous carcinoma. In our study
population, the age range for patients with low-grade serous
carcinoma was rather large, but the median age of 44 years was
much younger than that of patients with high-grade serous
carcinoma (54 years) and there were more premenopausal
women in the low-grade carcinoma group. These findings were
similar to a previous report from M. D. Anderson that the
median age at diagnosis was 43 years
23 and the median age of
women with epithelial ovarian cancer (approximately 90% of
which are high grade carcinoma) was 59-60 years.
24,25 In
addition, low-grade serous tumors were diagnosed in more
early stage (stage I and II). There were no statistically
significant differences in prognosis according to FIGO stage
between the two groups, but the low-grade carcinoma group
showed a trend for improved progression-free survival
compared with the high-grade carcinoma group of early stage.
Our results add to previous studies that low-grade serous
carcinoma is slow-glowing indolent neoplasm, but shows
different feature from previous study that low-grade carcinoma
is characterized by prolonged survival in advanced stage.
23,26
However, these data indicate the possibility that low-grade and
high-grade serous carcinomas are two different tumor types,
each with their own pathogenesis rather than different grades of
the same neoplasm. 
In a previous mutation study, KRAS mutations were observed
in approximately 50% of serous tumors with low malignant
potential and low-grade serous carcinomas, however, no KRAS
mutations were found in high-grade serous carcinomas.
2
Subsequent studies confirmed these previous results and found
Yun-Hyun Cho, et al.
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Fig. 3. Chromatograms of TP53 nucleotide sequences. Nucleotide sequences determined by chromatograms are shown for different types of TP53 mutations.
(A)Ser127Pro (TCC > CCC). (B) His179Arg(CAT > CGT). (C) nt. 583 A del. (D) Arg213Term (CGA > TGA). 
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Fig. 2. (A) A point mutation of the KRAS gene in low-grade serous carcinoma in codon 12, GGT → GAT. (B) A BRAF mutation in a low-grade serous carcinoma in exon
15, position 600, substitution of A for T, GTG → GAG.
A Beither BRAF or KRAS mutations in 68% of low-grade serous
carcinomas and in 61% of serous tumors of low malignant
potential, but in none of the high-grade serous carcinomas.
4
Furthermore, none of the low-grade tumors contained muta-
tions in both KRAS and BRAF, indicating that these mutations
are mutually exclusive. It has also been suggested that analysis
of the other components of this pathway will reveal other
mutations in the 40% of cases without KRAS and BRAF
mutation. As alternate pathways, TP53 and PTEN/PIK3CA
mutations were suggested.
1 The main role of PTEN is a
phosphatase activity, antagonizing the PI3 kinase/AKT
pathway; that is, by keeping ART inactive and protecting p53
from degradation.
27 In the present study, KRAS mutations were
found in 30%, BRAF mutations were found in 10%, and KRAS
or BRAF mutations were found in 40% of low-grade serous
carcinomas, whereas no BRAF or KRAS mutations were found
in high-grade serous carcinoma. However, our study reported
lower frequencies of KRAS or BRAF mutations than previous
studies, and we suggest that the number of carcinomas due to
mutation of another pathway-activating factor might be greater
in Korean individuals.     
Mutational alteration of the TP53 gene was reported in 30-
80% of cases of epithelial ovarian cancer,
16,28,29 but few studies
directly compared the expression of TP53 in low-grade and
high-grade serous carcinomas. A recent study found functional
TP53 mutations in only one of 12 (8.3%) low-grade serous
carcinomas and in 30 of 59 (50.8%) high-grade serous
carcinomas.
13 The present study found TP53 mutations in
20.0% of low-grade serous carcinomas and 70.6% of high-
grade serous carcinomas, which is significantly greater than the
incidence of low-grade serous carcinoma, but similar to the
incidence of high-grade serous carcinoma previously reported.
In this study, we found slightly increased incidences of TP53
mutation in both groups compared with the previous study.
However, based on the finding that there were TP53 mutations
without combined KRAS or BRAF mutations in 20.0% of low-
grade serous carcinomas, the possibility that they are involved
in progression of low-grade to high-grade serous carcinomas
cannot be excluded. In addition, the possibility that other
pathways are involved should also be considered. Shih et al.
11
described a micropapillary pattern simulating low-grade serous
carcinoma which have had TP53 mutations and lacked
mutations of KRAS or BRAF. These tumors displaying a
micropapillary architecture developed from a subset of low-
grade serous carcinomas that lacked mutation of KRAS and
BRAF and subsequently acquired a TP mutation, which in turn
might increase the level of nuclear atypia.
30 We suggest that the
above described suggestions might be able to explain higher
frequency of TP53 mutation in Korean women.  
In conclusion, our findings support those of earlier clinical
studies that low-grade serous carcinomas seem to have age
distribution and mutational pattern distinct from high-grade
serous carcinomas. However, there were no significant differ-
ences in stage distribution and survival, especially in advanced
stage, between 2 groups, we therefore suggest that more studies
are needed to segregate these patients into distinct disease
entities.  
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